Effects of Statin Treatment on Cardiac Function in Patients With Chronic Heart Failure: A Meta‐Analysis of Randomized Controlled Trials
- 10 December 2010
- journal article
- research article
- Published by Wiley in Clinical Cardiology
- Vol. 34 (2), 117-123
- https://doi.org/10.1002/clc.20821
Abstract
Background Whether additional benefit can be achieved with the use of statin treatment in patients with chronic heart failure (CHF) remains undetermined. Hypothesis Statin treatment may be effective in improving cardiac function and ameliorating ventricular remodeling in CHF patients. Methods The PubMed, MEDLINE, EMBASE, and EBM Reviews databases were searched for randomized controlled trials comparing statin treatment with nonstatin treatment in patients with CHF. Two reviews independently assessed studies and extracted data. Weighted mean differences (WMD) with 95% confidence intervals (CI) were calculated using random effects models. Results Eleven trials with 590 patients were included. Pooled analysis showed that statin treatment was associated with a significant increase in left ventricular ejection fraction (WMD: 3.35%, 95% CI: 0.80 to 5.91%, P = 0.01). The beneficial effects of statin treatment were also demonstrated by the reduction of left ventricular end‐diastolic diameter (WMD: −3.77 mm, 95% CI: −6.24 to −1.31 mm, P = 0.003), left ventricular end‐systolic diameter (WMD: −3.57 mm, 95% CI: −6.37 to −0.76 mm, P = 0.01), B‐type natriuretic peptide (WMD: −83.17 pg/mL, 95% CI: −121.29 to −45.05 pg/mL, P < 0.0001), and New York Heart Association functional class (WMD: −0.30, 95% CI: −0.37 to −0.23, P < 0.00001). Meta‐regression showed a statistically significant association between left ventricular ejection fraction improvement and follow‐up duration (P = 0.03). Conclusions The current cumulative evidence suggests that use of statin treatment in CHF patients may result in the improvement of cardiac function and clinical symptoms, as well as the amelioration of left ventricular remodeling. Copyright © 2011 Wiley Periodicals, Inc. Lei Zhang, MD, Shuning Zhang, MD, and Hong Jiang, MD, contributed equally to this work. This study was supported by the Key Projects in the National Science and Technology Pillar Program in the Eleventh Five‐year Plan Period (No. 2006BAI01A04), National Natural Science Foundation of China (No. 30871073), National High‐Tech Research and Development Program of China (No. 2006AA02A406), and Outstanding Youth Grant from National Natural Science Foundation of China (No. 30725036). This work was not funded by an industry sponsor. The authors have no other funding, financial relationships, or conflicts of interest to disclose. Additional Supporting Information may be found in the online version of this article.Keywords
This publication has 40 references indexed in Scilit:
- Effects of Statin Therapy According to Plasma High-Sensitivity C-Reactive Protein Concentration in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA)Circulation, 2009
- Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trialThe Lancet, 2008
- Short-term statin treatment improves endothelial function and neurohormonal imbalance in normocholesterolaemic patients with non-ischaemic heart failureHeart, 2006
- Usefulness of Atorvastatin in Patients With Heart Failure Due to Inflammatory Dilated Cardiomyopathy and Elevated Cholesterol LevelsThe American Journal of Cardiology, 2006
- Neutral Effect on Markers of Heart Failure, Inflammation, Endothelial Activation and Function, and Vagal Tone After High-Dose HMG-CoA Reductase Inhibition in Non-Diabetic Patients With Non-Ischemic Cardiomyopathy and Average Low-Density Lipoprotein LevelJournal of the American College of Cardiology, 2006
- Atorvastatin Therapy Increases Heart Rate Variability, Decreases QT Variability, and Shortens QTc Interval Duration in Patients With Advanced Chronic Heart FailureJournal of Cardiac Failure, 2005
- The Effects of Atorvastatin (10 mg) on Systemic Inflammation in Heart FailureThe American Journal of Cardiology, 2005
- IN VITRO INHIBITORY EFFECTS OF ATORVASTATIN ON CARDIAC FIBROBLASTS: IMPLICATIONS FOR VENTRICULAR REMODELLINGClinical and Experimental Pharmacology and Physiology, 2005
- Plasma B-type natriuretic peptide reflects left ventricular hypertrophy and diastolic function in hypertensionInternational Journal of Cardiology, 2004
- Statins as antioxidant therapy for preventing cardiac myocyte hypertrophyJCI Insight, 2001